Therapy outcomes of IL-17 and JAK inhibitors in rosacea: A systematic review

Xinyi Dai; Chenxingyue Zhang; Zhiqiang Yin

doi:10.7555/JBR.38.20240107

Journal of Biomedical Research ›› 2025, Vol. 39 ›› Issue (3) :317 -318. DOI: 10.7555/JBR.38.20240107

Letter to the Editor

research-article

Therapy outcomes of IL-17 and JAK inhibitors in rosacea: A systematic review

Author information +

History +

PDF (1762KB)

Cite this article

Download citation ▾

Xinyi Dai, Chenxingyue Zhang, Zhiqiang Yin. Therapy outcomes of IL-17 and JAK inhibitors in rosacea: A systematic review. Journal of Biomedical Research, 2025, 39(3): 317-318 DOI:10.7555/JBR.38.20240107

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Buhl T, Sulk M, Nowak P, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways[J]. J Invest Dermatol, 2015, 135(9): 2198-2208. doi: 10.1038/jid.2015.141

[2]	Chen C, Wang P, Zhang L, et al. Exploring the pathogenesis and mechanism-targeted treatments of rosacea: previous understanding and updates[J]. Biomedicines, 2023, 11(8): 2153. doi: 10.3390/biomedicines11082153

[3]	Fisher GW, Travers JB, Rohan CA. Rosacea pathogenesis and therapeutics: current treatments and a look at future targets[J]. Front Med, 2023, 10: 1292722. doi: 10.3389/fmed.2023.1292722

[4]	Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis[J]. Br J Pharmacol, 2010, 159(4): 842-855. doi: 10.1111/j.1476-5381.2009.00559.x

[5]	Asena L, Akova YA, Cetinkaya A, et al. The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization[J]. Acta Ophthalmol, 2012, 91(3): e246-e248. doi: 10.1111/j.1755-3768.2012.02540.x